HK1199744A1 - Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status rnf43 wnt - Google Patents

Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status rnf43 wnt

Info

Publication number
HK1199744A1
HK1199744A1 HK15100179.6A HK15100179A HK1199744A1 HK 1199744 A1 HK1199744 A1 HK 1199744A1 HK 15100179 A HK15100179 A HK 15100179A HK 1199744 A1 HK1199744 A1 HK 1199744A1
Authority
HK
Hong Kong
Prior art keywords
rnf43
wnt
administration
cancer patient
mutation status
Prior art date
Application number
HK15100179.6A
Other languages
English (en)
Chinese (zh)
Inventor
Feng Cong
Huaixiang Hao
Hsin-I Hsieh
Xiaomo Jiang
Jun Liu
Nicholas Ng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47790546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1199744A1 publication Critical patent/HK1199744A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15100179.6A 2012-02-28 2015-01-08 Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status rnf43 wnt HK1199744A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261604290P 2012-02-28 2012-02-28
PCT/US2013/027441 WO2013130364A1 (fr) 2012-02-28 2013-02-22 Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43

Publications (1)

Publication Number Publication Date
HK1199744A1 true HK1199744A1 (en) 2015-07-17

Family

ID=47790546

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100179.6A HK1199744A1 (en) 2012-02-28 2015-01-08 Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status rnf43 wnt

Country Status (20)

Country Link
US (3) US20150125857A1 (fr)
EP (2) EP2820151B1 (fr)
JP (2) JP6397335B2 (fr)
KR (1) KR20140132712A (fr)
CN (1) CN104302782A (fr)
AU (1) AU2013226323B2 (fr)
BR (1) BR112014020233A2 (fr)
CA (1) CA2864306A1 (fr)
CL (1) CL2014002269A1 (fr)
ES (2) ES2968742T3 (fr)
HK (1) HK1199744A1 (fr)
IL (1) IL233920A0 (fr)
MX (1) MX2014010265A (fr)
NZ (1) NZ627864A (fr)
PH (1) PH12014501930A1 (fr)
RU (2) RU2017120287A (fr)
SG (1) SG11201404492VA (fr)
TN (1) TN2014000337A1 (fr)
WO (1) WO2013130364A1 (fr)
ZA (1) ZA201405553B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
EP2766033B1 (fr) 2011-10-14 2019-11-20 Novartis AG Anticorps et méthodes pour traiter des maladies associées à la voie de signalisation wnt
KR20140132712A (ko) 2012-02-28 2014-11-18 노파르티스 아게 RNF43 돌연변이 상태를 사용한 Wnt 신호전달 억제제의 투여를 위한 암 환자 선택
EP2968348A4 (fr) 2013-03-12 2016-11-09 Curegenix Inc Composés pour le traitement du cancer
WO2015145388A2 (fr) * 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
KR20170010764A (ko) * 2014-04-21 2017-02-01 애브비 스템센트알엑스 엘엘씨 신규한 항-ｒｎｆ43 항체 및 사용 방법
KR102525131B1 (ko) * 2014-10-08 2023-04-24 레드엑스 파마 피엘씨 Wnt 신호 경로의 억제제로서의 N-피리디닐 아세트아미드 유도체
US20160312207A1 (en) * 2015-04-21 2016-10-27 The Board Of Trustees Of The Leland Stanford Junior University R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling
JP2018522062A (ja) * 2015-05-26 2018-08-09 キュアジェニックス コーポレーション 腫瘍バイオマーカー及びその使用
WO2018132572A1 (fr) 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University Molécules de substitution de r-spondine (rspo)
AU2018211985A1 (en) * 2017-01-26 2019-07-18 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
WO2019245460A1 (fr) * 2018-06-21 2019-12-26 National University Of Singapore Stratification de patients cancéreux hébergeant des mutations oncogènes dans l'ubiquitine ligase e3 rnf43
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
US11713461B2 (en) 2019-06-21 2023-08-01 Regeneran Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors
CN113564249B (zh) * 2020-04-28 2023-06-16 中国科学院分子细胞科学卓越创新中心 CXorf67在判断肿瘤对DNA损伤药物的敏感性中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531674A (en) 2001-09-18 2009-03-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
KR101031025B1 (ko) 2002-06-06 2011-04-25 온코세라피 사이언스 가부시키가이샤 사람 결장암에 관계하는 유전자 및 폴리펩티드
CN101613405A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
WO2004086949A2 (fr) 2003-03-25 2004-10-14 John Wayne Cancer Institute Marqueurs d'adn utilises dans la gestion du cancer
MX2007000364A (es) * 2004-07-09 2007-06-25 Univ California Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16.
AU2005302846A1 (en) * 2004-11-10 2006-05-18 Hubrecht Laboratorium Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
DE602006016085D1 (de) 2005-03-16 2010-09-23 Genentech Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011004379A1 (fr) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions et méthodes de traitement du cancer
EP2549399A1 (fr) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Evaluation d'activité de voie Wnt utilisant un modelage probabilistique d'expression de gène cible
EP2766033B1 (fr) 2011-10-14 2019-11-20 Novartis AG Anticorps et méthodes pour traiter des maladies associées à la voie de signalisation wnt
KR20140132712A (ko) 2012-02-28 2014-11-18 노파르티스 아게 RNF43 돌연변이 상태를 사용한 Wnt 신호전달 억제제의 투여를 위한 암 환자 선택
EP3797790A1 (fr) 2015-12-04 2021-03-31 Boehringer Ingelheim International GmbH Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales

Also Published As

Publication number Publication date
EP2820151A1 (fr) 2015-01-07
RU2014139044A (ru) 2016-04-20
US20150125857A1 (en) 2015-05-07
JP6397335B2 (ja) 2018-09-26
AU2013226323B2 (en) 2016-07-14
RU2017120287A (ru) 2018-11-15
IL233920A0 (en) 2014-09-30
ES2968742T3 (es) 2024-05-13
CL2014002269A1 (es) 2014-12-19
AU2013226323A1 (en) 2014-09-11
RU2636000C2 (ru) 2017-11-17
JP2018172408A (ja) 2018-11-08
MX2014010265A (es) 2015-06-23
ES2797533T3 (es) 2020-12-02
BR112014020233A2 (pt) 2017-07-04
EP2820151B1 (fr) 2020-03-25
PH12014501930A1 (en) 2014-11-24
NZ627864A (en) 2015-12-24
KR20140132712A (ko) 2014-11-18
CA2864306A1 (fr) 2013-09-06
US20190203301A1 (en) 2019-07-04
US20170306409A1 (en) 2017-10-26
WO2013130364A1 (fr) 2013-09-06
EP3693476B1 (fr) 2023-10-18
EP3693476A1 (fr) 2020-08-12
CN104302782A (zh) 2015-01-21
TN2014000337A1 (en) 2015-12-21
ZA201405553B (en) 2015-12-23
JP2015511484A (ja) 2015-04-20
SG11201404492VA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
HK1199744A1 (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status rnf43 wnt
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
PL2818482T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
PL2824114T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
IL232128B (en) Tor kinase inhibitors for cancer treatment
HK1202247A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1201750A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1201753A1 (en) Treatment of cancer with tor kinase inhibitors tor
EP2903644A4 (fr) Traitement du cancer
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
EP2817011A4 (fr) Traitement du cancer
HK1223832A1 (zh) 用於癌症治療的激酶抑制劑
EP2897607A4 (fr) Inhibiteurs de bêta-hydrolase pour le traitement du cancer
EP2849786A4 (fr) Méthodes de traitement d'un cancer gastrique
IL237229A0 (en) Methods of treating cancer using lipoplatin
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors
HK1200094A1 (en) Use of immunomodulators for the treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20240221